Gaudium IVF and Women Health Limited, a leading fertility and women’s healthcare provider in India, announced its financial performance for the quarter and nine months ended 31 December 2025. Source: BSE

Financial Performance: Key Details

Revenue from operations stood at ₹2,450.70 lakh in Q3 FY 2026 as compared to ₹1,442.50 lakh for Q3 FY 2025, up 70% y-o-y (down 23 percent Q-o-Q)

Total income was ₹2,461.00 lakh for Q3 FY 2026 as against ₹1,442.50 lakh for Q3 FY 2025.

Profit Before Tax (PBT) was ₹496.31 lakh in Q3 FY 2026 vs ₹469.32 lakh in Q3 FY 2025

Net Profit for Q3 FY 2026 stood at ₹363.05 lakh as compared to ₹339.77 lakh in Q3 FY 2025, up 6.77% y-o-y (down 61 percent Q-o-Q)

The Company maintained healthy margins during the period, supported by operating leverage and disciplined cost management.

Gaudium IVF and Women Health Q3 FY 2026

Management Speech –

Commenting on financial performance, Dr. Manika Khanna, Chairperson and Managing Director, Gaudium IVF and Women Health Limited, said

This is not just a quarter of strong performance, it reflects a category that is coming of age, and Gaudium IVF is at the forefront of shaping it.

Our listing marks a structural shift, from building a trusted clinical brand to institutionalising a scalable, future-ready healthcare platform.

We have been deliberate in how we grow, combining clinical excellence with operational discipline.

The opportunity in fertility care in India is significantly underpenetrated, and we see ourselves not just participating in this growth but leading it.

Our focus is clear, expand, access, deepen outcomes, and build India’s most trusted & outcome-driven fertility network.

Refer to gaudium ivf share news for further details.

The stock ended at INR 80.55 (down 15%) on the National Stock Exchange on Thursday, March 19, 2026.

ALSO READ: Central Mine Planning & Design Institute IPO Review

Disclaimer: The contents and data presented here are just for your information & personal use only. While much effort is made to provide the information, I (Vishal Dalwadi) or “FinBlab” do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.

The post Gaudium IVF and Women Health Q3 FY 2026 appeared first on Upcoming ipos: Latest news on stocks, economy & finance.

Gaudium IVF IPO “Listing”

Gaudium IVF and Women’s Health Ltd, a company that specializes in fertility and reproductive health services, made a muted debut on the stock market on February 27, 2026.

The muted listing came despite the company’s ₹165 Crores IPO receiving a decent subscription of 7.27 times (according to stock exchange data) during February 20-24.

ALSO READ – kirloskar brothers latest news

The shares of Gaudium IVF were listed at ₹83 apiece on the National Stock Exchange (NSE), against the IPO price of ₹79, representing a premium of about 5%.

The Stock made a high of ₹87.15 and a low of ₹79.50 before closing at ₹80.40 (up 1.77%) on the NSE at the market’s close.

In terms of volumes,  Gaudium_IVF traded with 8,849,112 shares on the NSE.

Do come back to know more about “upcoming ipos“

17 February 2026

Gaudium IVF and Women Health Limited, a company engaged in the IVF treatment in India, is planning to raise ₹165 crore through an Initial Public Offering.

[Fresh Issue ₹90 Cr + OFS ₹75 Cr]

Gaudium ivf ipo price is ₹75 – ₹79 per share

Gaudium IVF: History

The company was originally incorporated as Gaudium IVF and Women Health Private Limited, as a private limited company under the provisions of the Companies Act, 2013, on March 24, 2015.

The Company was then converted into a public limited company under a special resolution passed by the shareholders on September 28, 2024. Its name was subsequently changed to Gaudium IVF and Women Health Limited under a fresh certificate of incorporation issued by the Registrars of Companies on October 24, 2024.

Gaudium IVF: Business

Incorporated in 2015, Gaudium IVF and Women Health Ltd. is engaged in IVF (In Vitro Fertilization) treatment across India and has extended into several states in the country using a hub-and-spoke model.

The Company offers a vast range of specialized fertility and reproductive health services. Its advanced treatments include –

• In Vitro Fertilization (IVF),
• Intracytoplasmic Sperm Injection (ICSI),
• Intrauterine Insemination (IUI), and
• Ovulation Induction (OI).

All the treatments offered by the company are meticulously designed to address a variety of infertility challenges for both females and males.

It also offers a complete range of gynecological care treatment, including Polycystic Ovarian Disease (PCOD)/ Polycystic Ovary Syndrome (PCOS) and endometriosis.

The Company also provides a vast range of male infertility treatments, including advanced sperm retrieval techniques.

It also offers cryopreservation services for egg freezing for future fertilization, utilizing state-of-the-art technology to ensure optimal success rates in future IVF cycles.

Gaudium IVF also offers hysteroscopic and laparoscopic surgeries for the diagnosis and treatment of infertility-related issues, as well as genetic testing options, including Preimplantation Genetic Testing (PGT).

PAN-India Presence

The company operates with more than 30 locations in India, which comprises,

• 7 hubs (IVF centers), and
• 28 spokes (the company has entered into a strategic alliance with Spokes Infertility Expert for spreading awareness about IVR and Assisted Reproductive Technology (ART) treatment).

Overseas Patients

The company also serves patients from foreign countries, including Canada, Kenya, Oman, the United Kingdom, the United States, and South Africa.

LAST ARTICLE – Tenneco Clean Air news

Strategies Ahead

• Establishment of New IVF Centers
• Launching of FMCG Products through EKK Global (a Wholly Owned Subsidiary of the company)

Company Promoters

1. Dr. Manika Khanna,
2. Dr. Peeyush Khanna,
3. Vishad Khanna.

Refer to Gaudium IVF DRHP for detailed information.

IPO Details

Gaudium ivf ipo date: 20 Feb – 24 Feb 2026

Minimum Amount: ₹14,931

Minimum Bid: 189 Shares

Face Value: ₹5

Listing On: NSE, BSE

Financial

Book Running Lead Manager

Sarthi Capital Advisors

CONCLUSION

FinBlab recommends ‘SUBSCRIBE‘ ratings on Gaudium IVF IPO.

Do come back to know more about “upcoming ipos“

Disclaimer: The contents and data presented here are just for your information & personal use only. While much effort is made to provide the information, I (Vishal Dalwadi) or “FinBlab” do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.

The post Gaudium IVF IPO Review, Update appeared first on Upcoming ipos: Latest news on stocks, economy & finance.